Portola Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 9 PAGES: 60

More Info
									Portola Pharmaceuticals, Inc. – Product Pipeline Review




          Portola Pharmaceuticals, Inc. – Product Pipeline
                        Review – H2 2011


                                                                                          Reference Code: GMDHC02080CDB
                                                                                                 Publication Date: DEC 2011




Portola Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                         GMDHC02080CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Portola Pharmaceuticals, Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Portola Pharmaceuticals, Inc. Snapshot ............................................................................................................................................. 5
    Portola Pharmaceuticals, Inc. Overview ........................................................................................................................................ 5
    Key Information ............................................................................................................................................................................. 5
    Key Facts....................................................................................................................................................................................... 5
Portola Pharmaceuticals, Inc. – Research and Development Overview ............................................................................................. 6
    Key Therapeutic Areas .................................................................................................................................................................. 6
Portola Pharmaceuticals, Inc. – Pipeline Review ............................................................................................................................... 9
    Pipeline Products by Stage of Development ................................................................................................................................. 9
    Pipeline Products – Monotherapy ............................................................................................................................................... 10
Portola Pharmaceuticals, Inc. – Pipeline Products Glance ............................................................................................................... 11
    Portola Pharmaceuticals, Inc. Clinical Stage Pipeline Products .................................................................................................. 11
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 11
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 12
    Portola Pharmaceuticals, Inc. – Early Stage Pipeline Products ................................................................................................... 13
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 13
Portola Pharmaceuticals, Inc. – Drug Profiles .................................................................................................................................. 14
    Betrixaban ................................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    JAK3 Program ............................................................................................................................................................................. 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    PRT062070 ................................................................................................................................................................................. 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 17
    PRT062607 ................................................................................................................................................................................. 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress ......................................................................................................................................................................... 18
    PRT064445 ................................................................................................................................................................................. 19
        Product Description................................................................................................................................................................. 19
        Mechanism of Action ............................................................................................................................................................... 19
        R&D Progress ......................................................................................................................................................................... 19
Portola Pharmaceuticals, Inc. – Pipeline Analysis ............................................................................................................................ 20
    Portola Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class.................................................................................... 20
    Portola Pharmaceuticals, Inc. - Pipeline Products By Target ...................................................................................................... 21



Portola Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                                                                      GMDHC02080CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
Portola Pharmaceuticals, Inc. – Product Pipeline Review




    Portola Pharmaceuticals, Inc. – Pipeline Products by Route of Administration ........................................................................... 22
    Portola Pharmaceuticals, Inc. – Pipeline Products by Molecule Type ......................................................................................... 23
Portola Pharmaceuticals, Inc. – Recent Pipeline Updates............................................................................................................... 24
Portola Pharmaceuticals, Inc. – Locations And Subsidiaries ............................................................................................................ 26
    Head Office.................................................................................................................................................................................. 26
Company's Recent Developments ................................................................................................................................................... 27
    Portola Pharmaceuticals, Inc., Recent Developments ................................................................................................................. 27
         Mar 31, 2011: Portola Initiates Phase I Multiple Ascending Dose Trial of Oral Syk-Specific Inhibitor ..................................... 27
         Aug 29, 2010: Portola Reports Pharmacodynamic Data From Phase II Trial Of Betrixaban .................................................. 27
         Mar 24, 2010: Portola Initiates Phase I Trial Of PRT062607 For Chronic Inflammatory Disease Indications ......................... 28
         Mar 16, 2010: Portola And Merck Announce Phase II Results Of Betrixaban ........................................................................ 29
         Nov 15, 2010: Portola Announces Factor Xa Inhibitor Antidote Reverses Anticoagulant Activity Of Factor Xa Inhibitors ...... 30
         Aug 11, 2011: Portola Pharmaceuticals Announces Upcoming Oral Presentation Of Factor Xa Inhibitor Antidote Data At ESC
         2011 Congress........................................................................................................................................................................ 30
         Jul 11, 2006: Portola Announces Initiation Of Phase II Clinical Trial With Factor Xa Inhibitor ................................................ 31
         Jul 10, 2007: Portola Pharmaceuticals Announces Positive Data From A Phase II Study Of Its Factor Xa Inhibitor At The XXI
         Congress Of The International Society On Thrombosis And Haemostasis ............................................................................. 32
         Feb 10, 2010: Portola Pharmaceuticals To Present Phase II Results Of Betrixaban At American College of Cardiology’s 59th
         Annual Scientific Session ........................................................................................................................................................ 32
         Dec 06, 2010: Preclinical Study Results For Syk, JAK Inhibitor Program ............................................................................... 33
         Apr 04, 2007: Portola Pharmaceuticals Announces Positive Phase II Results For PRT054021 For Prevention Of Venous
         Thromboembolism Following Total Knee Replacement Surgery ................................................................
								
To top